Gene transactivation without direct DNA binding defines a novel gain-of-function for PML-RAR alpha

Autor: Sake van Wageningen, Joop H. Jansen, Gorica Nikoloski, Claudia A.J. Erpelinck-Verschueren, Marleen C. Breems-de Ridder, Bob Löwenberg, Theo de Witte, Daniel G. Tenen, Jeannet Nigten, Bert A. van der Reijden
Přispěvatelé: Hematology, Virology
Rok vydání: 2008
Předmět:
Inhibitor of Differentiation Protein 1
Transcriptional Activation
Oncogene Proteins
Fusion

Receptors
Retinoic Acid

Sp1 Transcription Factor
Molecular Sequence Data
Immunology
Tretinoin
Biology
Retinoid X receptor
Biochemistry
Metabolism
transport and motion [NCMLS 2]

Transactivation
Leukemia
Promyelocytic
Acute

Immune Regulation [NCMLS 2]
Translational research [ONCOL 3]
Transcription (biology)
Cell Line
Tumor

Iron metabolism [IGMD 7]
Humans
Promoter Regions
Genetic

Transcription factor
Molecular diagnosis
prognosis and monitoring [UMCN 1.2]

Sp1 transcription factor
Retinoic Acid Receptor alpha
Immunotherapy
gene therapy and transplantation [UMCN 1.4]

Promoter
DNA
Cell Biology
Hematology
Molecular biology
Fusion protein
Up-Regulation
Pathogenesis and modulation of inflammation [N4i 1]
Retinoid X Receptors
CCAAT-Binding Factor
Retinoic acid receptor alpha
embryonic structures
Protein Binding
Zdroj: Blood, 111(3), 1634-1643. American Society of Hematology
Blood, 111, 3, pp. 1634-43
Blood, 111, 1634-43
ISSN: 0006-4971
Popis: PML-RARα is the causative oncogene in 5% to 10% of the cases of acute myeloid leukemia. At physiological concentrations of retinoic acid, PML-RARα silences RARα target genes, blocking differentiation of the cells. At high concentrations of ligand, it (re)activates the transcription of target genes, forcing terminal differentiation. The study of RARα target genes that mediate this differentiation has identified several genes that are important for proliferation and differentiation control in normal and malignant hematopoietic cells. In this paper, we show that the PML-RARα fusion protein not only interferes with the transcription of regular RARα target genes. We show that the ID1 and ID2 promoters are activated by PML-RARα but, unexpectedly, not by wild-type RARα/RXR. Our data support a model in which the PML-RARα fusion protein regulates a novel class of target genes by interaction with the Sp1 and NF-Y transcription factors, without directly binding to the DNA, defining a gain-of-function for the oncoprotein.
Databáze: OpenAIRE